Psychoactive Substance Use Disorders

  • Steven M. Mirin
  • Roger D. Weiss
  • Shelly F. Greenfield


The self-administration of chemical substances that alter mood or thinking has been a widespread practice for centuries. When the use of such substances deviates from societal norms or is deemed harmful to physical or mental health, substance use may merge into substance abuse and dependence.


Acquire Immune Deficiency Syndrome Methadone Maintenance Treatment Methadone Maintenance Physical Dependence Opioid Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Reading


  1. 1.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.Google Scholar
  2. 2.
    Baldessarini R. J.: Chemotherapy in Psychiatry. Cambridge, Harvard University Press, 1985.Google Scholar
  3. 3.
    Braude M. C.: Perinatal effects of drugs of abuse: Symposium summary. Fed Proc 46:2446–2453, 1987.PubMedGoogle Scholar
  4. 4.
    Kozel N. J., Adams E. H.: Epidemiology of drug abuse: An overview. Science 234:970–974, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Meyer R. E. (ed): Psychopathology and Additive Disorders. New York, Guilford Press, 1986.Google Scholar
  6. 6.
    Mirin S. M. (ed): Substance Abuse and Psychopathology. Washington, American Psychiatric Press, 1984.Google Scholar
  7. 7.
    Mirin S. M., Weiss R. D., Michael J.: Psychopathology in substance abusers: Diagnosis and treatment. Am J Drug Alcohol Abuse 14:139–157, 1988.PubMedCrossRefGoogle Scholar


  1. 8.
    Bale R. N., Van Stone W. W., Kuldau J. M., et al: Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: Design and one-year follow-up. Arch Gen Psychiatry 37:179–193, 1980.PubMedCrossRefGoogle Scholar
  2. 9.
    Batki S. L., Sorensen J. L., Faltz B., et al: Psychiatric aspects of treatment of i. v. drug abusers with AIDS. Hosp Community Psychiatry 39:439–441, 1988.PubMedGoogle Scholar
  3. 10.
    Charney D. S., Riordan C. E., Kleber H. D.: Clonidine and naltrexone: A safe, effective and rapid treatment of abrupt withdrawal from methadone therapy. Arch Gen Psychiatry 39:1327–1332, 1982.PubMedCrossRefGoogle Scholar
  4. 11.
    Crabtree B. L. : Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 3:273–280, 1984.PubMedGoogle Scholar
  5. 12.
    Crowley T. J., Wagner J. E., Zerbe G.: Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 142:1081–1084, 1985.PubMedGoogle Scholar
  6. 13.
    Cushman P.: The major medical sequelae of opioid addiction. Drug Alcohol Dep 5:239–254, 1980.CrossRefGoogle Scholar
  7. 14.
    Davis D. D., Templer D. I.: Neurobehavioral functioning in children exposed to narcotics in utero. Addict Behav 13:275–283, 1988.CrossRefGoogle Scholar
  8. 15.
    Dole V. P.: Narcotic addiction, physical dependence and relapse. N Engl J Med 286:988–992, 1972.PubMedCrossRefGoogle Scholar
  9. 16.
    Dole V. P.: Implications of methadone maintenance for theories of narcotic addiction. JAMA 260:3025–3029, 1988.PubMedCrossRefGoogle Scholar
  10. 17.
    Dole V. P., Nyswander M. E.: Heroin addiction-a metabolic disease. Arch Intern Med 120:19–24, 1967.PubMedCrossRefGoogle Scholar
  11. 18.
    Edelin K. C., Gurganious L., Golar K.: Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 71:399–404, 1988.PubMedGoogle Scholar
  12. 19.
    Faltz B. G.: Counseling substance abuse clients infected with human immunodeficiency virus. J Psychoactive Drugs 20:217–221, 1988.PubMedCrossRefGoogle Scholar
  13. 20.
    Friedman A. S., Glickman N. W.: Residential program characteristics for completion of treatment by adolescent drug abusers. J Nerv Ment Dis 175:419–424, 1987.PubMedCrossRefGoogle Scholar
  14. 21.
    Greenstein R. A., Arndt I. C., et al: Naltrexone: A clinical perspective. J Clin Psychiatry 45:25–28, 1984.PubMedGoogle Scholar
  15. 22.
    Gritz E. R., Shiffman S. M., Jarvik M. E., McLellan A. T.: Physiological and psychological effects of methadone in man. Arch Gen Psychiatry 32:237–242, 1975.PubMedCrossRefGoogle Scholar
  16. 23.
    Haastrup S., Jepsen P. W.: Eleven year follow-up of 300 young opioid addicts. Acta Psychiatr Scand 77:22–26, 1988.PubMedCrossRefGoogle Scholar
  17. 24.
    Jaffe J. H.: Drug addiction and drug abuse, in Goodman L. S., Gilman A., Gilman A. G. (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 7. New York, Macmillan, 1985, pp 532–581.Google Scholar
  18. 25.
    Jaffe J. H., Martin W. R.: Opioid analgesics and antagonists, in Goodman L. S., Gilman A., Gilman A. G. (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 7. New York, Macmillan, 1985, pp 491–531.Google Scholar
  19. 26.
    Jasinski D. R., Pevnick J. S., Griffith J. D.: Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501–514, 1978.PubMedCrossRefGoogle Scholar
  20. 27.
    Kleber H. D.: Naltrexone. J Subst Abuse Treat 2:117–122, 1985.PubMedCrossRefGoogle Scholar
  21. 28.
    Kleber H. D.: Treatment of narcotic addicts. Psychiatric Med 3:389–418, 1987.Google Scholar
  22. 29.
    Kleber H. D., Kosten T. R.: Naltrexone induction: Psychologic and pharmacologic strategies. J Clin Psychiatry 45:29–38, 1984.PubMedGoogle Scholar
  23. 30.
    Kleber H. D., Riordan C. E., Rounsaville B.: Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 42:391–394, 1985.PubMedCrossRefGoogle Scholar
  24. 31.
    Kleber H. D., Slobetz F.: Outpatient drug-free treatment, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse. Washington, National Institute on Drug Abuse, 1979, pp 31–38.Google Scholar
  25. 32.
    Kosten T. R., Kleber H. D.: Buprenorphine detoxification from opioid dependence: A pilot study. Life Sci 42:635–641, 1988.PubMedCrossRefGoogle Scholar
  26. 33.
    Kosten T. R., Kleber H. D.: Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 11:249–266, 1984.Google Scholar
  27. 34.
    Kosten T. R., Rounsaville B. J.: Psychopathology in opioid addicts. Psychiatr Clin North Am 9:515–532, 1986.PubMedGoogle Scholar
  28. 35.
    Kreek M. J.: Medical safety and side effects of methadone in tolerant individuals. JAMA 223:665–668, 1973.PubMedCrossRefGoogle Scholar
  29. 36.
    Martin W. R.: Naloxone. Ann Intern Med 85:765–768, 1976.PubMedGoogle Scholar
  30. 37.
    Mello N. K., Mendelson J. H.: Buprenorphine suppresses heroin use by heroin addicts. Science 207:657–659, 1980.PubMedCrossRefGoogle Scholar
  31. 38.
    Meyer R. E., Mirin S. M.: The Heroin Stimulus: Implications for a Theory of Addiction. New York, Plenum Press, 1979.Google Scholar
  32. 39.
    Milby J. B.: Methadone maintenance to abstinence-how many make it? J Nerv Ment Dis 176:409–422, 1988.PubMedCrossRefGoogle Scholar
  33. 40.
    Mirin S. M., Meyer R. E., McNamee H. B.: Psychopathology and mood during heroin use. Arch Gen Psychiatry 33:1503–1508, 1976.PubMedCrossRefGoogle Scholar
  34. 41.
    Mirin S. M., Meyer R. E., Mendelson, J. H., et al: Opiate use and sexual function. Am J Psychiatry 137:909–915, 1980.PubMedGoogle Scholar
  35. 42.
    National Research Council Committee on Clinical Evaluation of Narcotic Antagonists: Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry 35:335–340, 1978.CrossRefGoogle Scholar
  36. 43.
    Newman R. G.: Methadone treatment-defining and evaluating success. N Engl J Med 317:447–450, 1987.PubMedCrossRefGoogle Scholar
  37. 44.
    O’Brien C. P., Testa T., O’Brien T. J., et al: Conditioned narcotic withdrawal in humans. Science 195:1000–1002, 1977.PubMedCrossRefGoogle Scholar
  38. 45.
    Resnick R. B., Schuyten-Resnick E., Washton A. M.: Treatment of opioid dependence with narcotic antagonists: A review and commentary, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse. Washington, National Institute on Drug Abuse, 1979, pp 76–104.Google Scholar
  39. 46.
    Rounsaville B. J., Kosten T., Kleber H.: Success and failure at outpatient detoxification. Evaluating the process of clonidine and methadone-assisted withdrawal. J Nerv Ment Dis 173:103–110, 1985.PubMedCrossRefGoogle Scholar
  40. 47.
    Rounsaville B. J., Weissman M. M., Crits-Cristoph K.: Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry 39:151–156, 1982.PubMedCrossRefGoogle Scholar
  41. 48.
    Schuster C. R.: Intravenous drug use and AIDS prevention. Public Health Rep 103:261–266, 1988.PubMedGoogle Scholar
  42. 49.
    Sells S. B.: Treatment effectiveness, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse. Washington, National Institute on Drug Abuse, 1979, pp 105–120.Google Scholar
  43. 50.
    Sells S. B., Simpson D. D. : The case for drug abuse treatment effectiveness, based on the DARP research program. Br J Addict 75:117–131, 1980.PubMedCrossRefGoogle Scholar
  44. 51.
    Senay E. C.: Methadone maintenance treatment. Int J Addict 20:803–821, 1985.PubMedGoogle Scholar
  45. 52.
    Simpson D. D., Savage L. J.: Drug abuse treatment readmissions and outcomes: Three-year follow-up of DARP patients. Arch Gen Psychiatry 37:896–901, 1980.PubMedCrossRefGoogle Scholar
  46. 53.
    Snyder S. H.: Opiate receptors in the brain. N Engl J Med 296:266–278, 1977.PubMedCrossRefGoogle Scholar
  47. 54.
    Stimmel B., Adamsons K. : Narcotic dependency in pregnancy: Methadone maintenance compared to use of street drugs. JAMA 235:1121–1124, 1976.PubMedCrossRefGoogle Scholar
  48. 55.
    US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration: Clinical management during pregnancy, in: Drug Dependence in Pregnancy: Clinical Management of Mother and Child. National Institute on Drug Abuse, Services Research Monograph Series, 1979, Chapter 3.Google Scholar
  49. 56.
    US Department of Health, Education and Welfare, Alcohol, Drug Abuse and Mental Health Administration: Management of labor, delivery and immediate post-partum period, in: Drug Dependence in Pregnancy: Clinical Management of Mother and Child. National Institute on Drug Abuse, Services Research Monograph Series, 1979, Chapter 4.Google Scholar
  50. 57.
    Vaillant G. E.: A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry 29:237–241, 1973.PubMedCrossRefGoogle Scholar
  51. 58.
    Washton A. M., Resnick R. B., Geyer G.: Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. J Clin Psychiatry 44:335–337, 1983.PubMedGoogle Scholar
  52. 59.
    Wikler A.: Dynamics of drug dependence. Arch Gen Psychiatry 28:611–616, 1973.PubMedCrossRefGoogle Scholar
  53. 60.
    Zelson C., Lee S. J., Casalino M. : Neonatal narcotic addiction: Comparative effects of maternal intake of heroin and methadone. N Engl J Med 289:1216–1220, 1973.PubMedCrossRefGoogle Scholar
  54. <BibsectionHD>Sedatives, Hypnotics, and Anxiolytics</BibsectionHD>Google Scholar
  55. 61.
    Abuse of benzodiazepines: The problems and the solutions. A report of a Committee of the Institute for Behavior and Health, Inc. Am J Drug Alcohol Abuse 14(Suppl 1):1–16, 1988.CrossRefGoogle Scholar
  56. 62.
    Braestrup C., Squires R. F.: Brain specific benzodiazepine receptors. Br J Psychiatry 133:249–260, 1978.PubMedCrossRefGoogle Scholar
  57. 63.
    Cohen L. S., Rosenbaum J. F.: Clonazepam: New uses and potential problems. J Clin Psychiatry 48(Suppl 10):50–55, 1987.PubMedGoogle Scholar
  58. 64.
    Cronin R. J., Klingler E. L., Jr., Avashti P. S., et al: The treatment of nonbarbiturate sedative overdosage, in Browne, P. G. (ed): A Treatment Manual for Acute Drug Abuse Emergencies. Washington, National Institute on Drug Abuse, 1974, pp 58–62.Google Scholar
  59. 65.
    Dorpat T. L.: Drug automatism, barbiturate poisoning and suicide behavior. Arch Gen Psychiatry 31:216–220, 1974.PubMedCrossRefGoogle Scholar
  60. 66.
    Dupont R. L. (ed): Abuse of benzodiazepines: The problems and the solutions. Am J Drug Alcohol Abuse 14(Suppl. 1):1–69, 1988.Google Scholar
  61. 67.
    Fleischhacker W. W., Barnas C., Hackenberg B.: Epidemiology of benzodiazepine dependence. Acta Psychiatr Scand 74(1):80–83, 1986.PubMedCrossRefGoogle Scholar
  62. 68.
    Gelenberg A. J.: Benzodiazepine withdrawal. Mass Gen Hosp Newslett Biol Ther Psychiatry Newslett 3:9–12, 1980.Google Scholar
  63. 69.
    Herman J. B., Rosenbaum J. F., Brotman A. W. : The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 7(3):175–178, 1987.PubMedCrossRefGoogle Scholar
  64. 70.
    Juergens S. M., Morse R. M.: Alprazolam dependence in seven patients. Am J Psychiatry 145(5):625–627, 1988.PubMedGoogle Scholar
  65. 71.
    Mellman T. A., Uhde T. W.: Withdrawal syndrome with gradual tapering of alprazolam. Am J Psychiatry 143(11):1464–1466, 1986.PubMedGoogle Scholar
  66. 72.
    Noyes R., Jr., Clancy J., Coryell W. H., et al: A withdrawal syndrome after abrupt discontinuation of alprazolam. Am J Psychiatry 142(1):114–116, 1985.PubMedGoogle Scholar
  67. 73.
    Noyes R., Jr., Perry P. J., Crowe R. R. : Seizures following the withdrawal of alprazolam. J Nerv Ment Dis 174(1):50–52, 1986.PubMedCrossRefGoogle Scholar
  68. 74.
    Pevnick J. S., Jasinski D. R., Haertzen C. A.: Abrupt withdrawal from therapeutically administered diazepam. Arch Gen Psychiatry 35:995–998, 1978.PubMedCrossRefGoogle Scholar
  69. 75.
    Piesiur-Strehlow B., Strelow U., Poser W.: Mortality of patients dependent on benzodiazepines. Acta Psychiatr Scand 73(3):330–335, 1986.PubMedCrossRefGoogle Scholar
  70. 76.
    Preskorn S. H., Denner L. J.: Benzodiazepines and withdrawal psychosis. Report of three cases. JAMA 237(1):36–38, 1977.PubMedCrossRefGoogle Scholar
  71. 77.
    Ray W. A., Blazer D. G., Schaffner W.: Reducing long-term diazepam prescribing in office practice. JAMA 256 (18):2536–2539, 1986.PubMedCrossRefGoogle Scholar
  72. 78.
    Setter J. G.: Emergency treatment of acute barbiturate intoxication, in Browne P. G. (ed): A Treatment Manual for Acute Drug Abuse Emergencies. Washington, National Institute on Drug Abuse, 1974, pp 49–53.Google Scholar
  73. 79.
    Smith D. E., Wesson D. R.: Phenobarbital technique for treatment of barbiturate dependence. Arch Gen Psychiatry 24:56–60, 1971.PubMedCrossRefGoogle Scholar
  74. 80.
    Smith D. E., Wesson D. R., Seymour R. B.: The abuse of barbiturates and other sedative— hypnotics, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse. Washington, National Institute on Drug Abuse, 1979, pp 233–240.Google Scholar
  75. 81.
    Swartzburg M., Lieb J., Schwartz A. H.: Methaqualone withdrawal. Arch Gen Psychiatry 29:46–47, 1973.PubMedCrossRefGoogle Scholar
  76. 82.
    Tennant F. S., Jr., Pumphrey E. A. : Benzodiazepine dependence of several years duration: clinical profile and therapeutic benefits. Natl Inst Drug Abuse Res Monogr 55:211–216, 1984.Google Scholar


  1. 83.
    Adams R. D., Victor M. : Principles of Neurology. New York, McGraw-Hill, 1985, pp 808–824.Google Scholar
  2. 84.
    Bean M.: Alcoholics Anonymous: Chapter I: Principles and methods. Psychiatr Ann 5:7–21, 1975.Google Scholar
  3. 85.
    Blume S. B.: Women and alcohol. A review. JAMA 256(11):1467–1470, 1986.PubMedCrossRefGoogle Scholar
  4. 86.
    Brown C. G.: The alcohol withdrawal syndrome. Ann Emerg Med 11(5):276–280, 1982.PubMedCrossRefGoogle Scholar
  5. 87.
    Ciraulo D. A., Barnhill J. G., Greenblatt D. J.: Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. J Clin Psychiatry 49(9):333–337, 1988.PubMedGoogle Scholar
  6. 88.
    Cloninger C. R.: Neurogenetic adaptive mechanisms in alcoholism. Science 236:410–416, 1987.PubMedCrossRefGoogle Scholar
  7. 89.
    Cohen S. (ed): The treatment of alcoholism: Does it work? Drug Abuse Alcoholism Newslett 7:1–3, 1978.Google Scholar
  8. 90.
    Coles C. D., Smith I., Fernhoff P. M.: Neonatal neurobehavioral characteristics as correlates of maternal alcohol use during gestation. Alcoholism (NY) 9(5):454–460, 1985.Google Scholar
  9. 91.
    Council on Scientific Affairs: Aversion Therapy. JAMA 258(18):2562–2566, 1987.CrossRefGoogle Scholar
  10. 92.
    Edwards G., Orford J., Egert S., et al: Alcoholism: A controlled trial of“treatment” and“advice.” J Stud Alcohol 38:1004–1031, 1977.PubMedGoogle Scholar
  11. 93.
    Emrick C. E.: A review of psychologically oriented treatment of alcoholism: II. The relative effectiveness of different treatment approaches and the effectiveness of treatment versus no treatment. J Stud Alcohol 36:88–108, 1975.PubMedGoogle Scholar
  12. 94.
    Emrick C. E.: Alcoholics Anonymous: Affilitation processes and effectiveness as treatment. Alcoholism (NY) 11(5):416–423, 1987.Google Scholar
  13. 95.
    Erhart C. B., Wolf A. W., Emhart C. B., Wolf A. W., Linn P. L.: Alcohol-related birth defects: Syndromal anomalies, intrauterine growth retardation, and neonatal behavioral assessment. Alcoholism (NY) 9(5):447–453, 1985.Google Scholar
  14. 96.
    Frances R. J.: Update on alcohol and drug disorder treatment. J Clin Psychiatry 49(Suppl):13–17, 1988.PubMedGoogle Scholar
  15. 97.
    Fuller R. K., Roth H. P.: Disulfiram for the treatment of alcoholism. Ann Intern Med 90:901–904, 1979.PubMedGoogle Scholar
  16. 98.
    Kwentus M. D., Major L. F.: Disulfiram in the treatment of alcoholism. J Stud Alcohol 40:428–446, 1979.PubMedGoogle Scholar
  17. 99.
    Linnoila M., Mefford I., Nutt D. W. : NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med 107(6):875–889, 1987.PubMedGoogle Scholar
  18. 100.
    Liskow B. I., Goodwin D. W. : Pharmacological treatment of alcohol intoxication, withdrawal and dependence: A critical review. J Stud Alcohol 48(4):356–370, 1987.PubMedGoogle Scholar
  19. 101.
    Liskow B., Mayfield D., Thiele J. : Alcohol and affective disorder: Assessment and treatment. J Clin Psychiatry 43(4):144–147, 1982.PubMedGoogle Scholar
  20. 102.
    Mendelson J. H., Babor T. F., Mello N. K., et al: Alcoholism and prevalence of medical and psychiatric disorders. J Stud Alcohol 47(5):361–366, 1986.PubMedGoogle Scholar
  21. 103.
    Mendelson J. H., Mello N. K.: Biologic concomitants of alcoholism. N Engl J Med 301:912–921, 1979.PubMedCrossRefGoogle Scholar
  22. 104.
    Mendelson J. H., Mello N. K. (eds): The Diagnosis and Treatment of Alcoholism, 2nd ed. New York. McGraw-Hill.Google Scholar
  23. 105.
    Meyer R. E., Kranzier H. R.: Alcoholism: Clinical implications of recent research. J Clin Psychiatry 49(Suppl):8–12, 1988.PubMedGoogle Scholar
  24. 106.
    Newsom G., Murray N.: Reversal of dexamethasone suppression test nonsuppression in alcohol abusers. Am J Psychiatry 140(3):353–354, 1983.PubMedGoogle Scholar
  25. 107.
    Ng S. K., Hauser W. A., Brust J. C.: Alcohol consumption and withdrawal in new-onset seizures. N Engl J Med 319(11):666–673, 1988.PubMedCrossRefGoogle Scholar
  26. 108.
    Ouelette E. M., Rosett H. L., Rosman N. P., et al: Adverse effects on offspring of maternal alcohol abuse during pregnancy. N Engl J Med 297:528–530, 1977.CrossRefGoogle Scholar
  27. 109.
    Pomerleau O., Pertschuk M., Stunnett J.: A critical examination of some current assumptions in the treatment of alcoholism. J Stud Alcohol 37:849–867, 1976.PubMedGoogle Scholar
  28. 110.
    Schuckit M. A.: A clinical review of alcohol, alcoholism and the elderly patient. J Clin Psychiatry 43:396–399, 1982.PubMedGoogle Scholar
  29. 111.
    Sellers E. M., Naranjo C. A., Peachey J. E. : Drug therapy: Drugs to decrease alcohol consumption. N Engl J Med 305(21):1255–1262, 1981.PubMedCrossRefGoogle Scholar
  30. 112.
    Stabenau J. R.: Implications of family history of alcoholism, antisocial personality, and sex differences in alcohol dependence. Am J Psychiatry 141(10):1178–1182, 1984.PubMedGoogle Scholar
  31. 113.
    Staiesey N. L., Fried P. A. : Relationships between moderate maternal and alcohol consumption during pregnancy and infant neurological development. J Stud Alcohol 44(2):262–270, 1983.Google Scholar
  32. 114.
    Streissguth A. P., Clarren S. K., Jones K. L.: Natural history of the fetal alcohol syndrome: A 10 year follow-up of eleven patients. Lancet 2(8446):85–91, 1985.PubMedCrossRefGoogle Scholar
  33. 115.
    Streissguth A. P., Sampson P. D., Barr H. M. : Studying alcohol teratogenesis from the perspective of the fetal alcohol syndrome: Methodological and statistical issues. Ann NY Acad Sci 488:73–86, 1986.Google Scholar
  34. 116.
    Thompson W. L., Johnson A. D., Maddrey W. L., et al: Diazepam and paraldehyde for treatment of severe delirium tremens: A controlled trial. Ann Intern Med 82:175–180, 1975.PubMedGoogle Scholar
  35. 117.
    Vaillant G. E.: The Natural History of Alcoholism: Causes, Patterns, and Paths of Recovery. Cambridge, MA, Harvard University Press, 1985.Google Scholar
  36. 118.
    Vaillant G. E.: Natural history of male psychological health: VIII. Antecedents of alcoholism and“orality.“ Am J Psychiatry 137:181–186, 1980.PubMedCrossRefGoogle Scholar
  37. 119.
    Warren K. R., Bast R. J.: Alcohol-related birth defects: An update. Public Health Rep 103(6):638–642, 1988.PubMedGoogle Scholar
  38. 120.
    Weissman M. M., Myers J. K.: Clinical depression in alcoholism. Am J Psychiatry 137:372–374, 1980.PubMedGoogle Scholar
  39. 121.
    Wilson G. T.: Chemical aversion conditioning as a treatment for alcoholism: A reanalysis. Behav Res Ther 25(6):503–516, 1987.PubMedCrossRefGoogle Scholar
  40. 122.
    Wright C., Vafier J. A., Lake C. R.: Disulfiram-induced fulminating hepatitis: Guidelines for liver panel monitoring. J Clin Psychiatry 49:430–434, 1988.PubMedGoogle Scholar


  1. 123.
    Aigner T. G., Balster R. L.: Choice behavior in rhesus monkeys: Cocaine versus food. Science 201:534–535, 1978.PubMedCrossRefGoogle Scholar
  2. 124.
    Byck R., Van Dyke C.: What are the effects of cocaine in man? in Peterson R. C., Stillman R. C. (eds): Cocaine: 1977. Washington, National Institute on Drug Abuse, Research Monograph 13, 1977, pp 5–16.Google Scholar
  3. 125.
    Chasnoff I., MacGregor S., Chisum G.: Cocaine use during pregnancy: Adverse perinatal outcome, in: Problems of Drug Dependence, 1987, Proceedings of the 49th Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. Washington, National Institute on Drug Abuse Research, Monograph 81, 1988, p 265.Google Scholar
  4. 126.
    Crack. Med Lett 28:69–70, 1986.Google Scholar
  5. 127.
    Cregler L. L., Mark H.: Special report: Medical complications of cocaine abuse. N Engl J Med 315:1495–1500, 1986.PubMedCrossRefGoogle Scholar
  6. 128.
    Ellinwood E. H., Jr.: Amphetamine psychosis: Individuals, settings and sequences, in Ellinwood E. H., Cohen S. (eds): Current Concepts on Amphetamine Abuse. Washington, National Institute of Mental Health, 1972, pp 143–158.Google Scholar
  7. 129.
    Ellinwood E. H., Jr.: Amphetamines/anorectics, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse. Washington, National Institute on Drug Abuse, 1979, pp 221–231.Google Scholar
  8. 130.
    Finnegan L.: The dilemma of cocaine exposure in the perinatal period, in: Problems of Drug Dependence, 1987, Proceedings of the 49th Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. Washington, National Institute on Drug Abuse, Research Monograph 81, 1988, p 379.Google Scholar
  9. 131.
    Fischman M. W., Schuster C. R., Resnekov L., et al: Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 33:983–989, 1976.PubMedCrossRefGoogle Scholar
  10. 132.
    Gawin F. H., Ellinwood E. H.: Cocaine and other stimulants: Actions, abuse and treatment. N Engl J Med 318:1173–1182, 1988.PubMedCrossRefGoogle Scholar
  11. 133.
    Gawin F. H., Kleber H. D.: Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: Clinical observations. Arch Gen Psychiatry 43:107–113, 1986.PubMedCrossRefGoogle Scholar
  12. 134.
    Gawin F. H., Kleber H. D.: Pharmacologic treatments of cocaine abuse. Psychiatr Clin North Am 9:573–583, 1986.PubMedGoogle Scholar
  13. 135.
    Gawin F. H., Kleber H. D., Byck R., et al: Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 46:117–121, 1989.PubMedCrossRefGoogle Scholar
  14. 136.
    Giannini A. J., Malone D. A., Giannini M. C.: Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. J Clin Pharmacol 26:211–214, 1986.PubMedGoogle Scholar
  15. 137.
    Grinspoon L., Hedblom P.: The Speed Culture: Amphetamine Use and Abuse in America. Cambridge, Harvard University Press, 1975.Google Scholar
  16. 138.
    Isner J. M., Estes M., Thompson P. D., et al: Acute cardiac events temporarily related to cocaine abuse. N Engl J Med 315:1438–1443, 1986.PubMedCrossRefGoogle Scholar
  17. 139.
    Javaid J. I., Fischman M. W., Schuster C. R., et al: Cocaine plasma concentration: Relation to physiological and subjective effects in humans. Science 202:227–228, 1978.PubMedCrossRefGoogle Scholar
  18. 140.
    Kramer J. C.: Introduction to amphetamine abuse, in Ellinwood E. H., Cohen S. (eds): Current Concepts on Amphetamine Abuse. Washington, National Institute of Mental Health, 1972, pp 177–184.Google Scholar
  19. 141.
    Kramer J. C., Fischman V. S., Littlefield D. C.: Amphetamine abuse: Pattern and effects of high doses taken intravenously. JAMA 201:89–93, 1967.CrossRefGoogle Scholar
  20. 142.
    Mody C. K., Miller B. L., McIntyre H. B., et al: Neurologic complications of cocaine abuse. Neurology 38:1189–1193, 1988.PubMedCrossRefGoogle Scholar
  21. 143.
    Pollack M. H., Brotman A. W., Rosenbaum J. F.: Cocaine abuse and treatment. Compr Psychiatry 30:31–44, 1989.PubMedCrossRefGoogle Scholar
  22. 144.
    Post R. M.: Cocaine psychoses: A continuum model. Am J Psychiatry 132:225–231, 1975.PubMedGoogle Scholar
  23. 145.
    Post R. M., Kotin J., Goodwin F. K.: The effects of cocaine on depressed patients. Am J Psychiatry 131:511–517, 1974.PubMedGoogle Scholar
  24. 146.
    Resnick R. B., Kestenbaum R. S.: Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes. Science 195:696–698, 1977.PubMedCrossRefGoogle Scholar
  25. 147.
    Rosenfeld W., Zabaleta I., Sahdev R., et al: Maternal use of cocaine, methadone, heroin and alcohol: Comparison of neonatal effects, in: Problems of Drug Dependence, 1987, Proceedings of the 49th Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. Washington, National Institute on Drug Abuse, Research Monograph 81, 1988, p 264.Google Scholar
  26. 148.
    Roth D., Alarcon F. J., Fernandez J. A.: Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med 319:673–677, 1988.PubMedCrossRefGoogle Scholar
  27. 149.
    Smith D. E., Wesson D. R., Buxton M. E., et al (eds): Amphetamine Use, Misuse and Abuse: Proceedings of the National Conference. Boston, G. K. Hall, 1979.Google Scholar
  28. 150.
    Washton A. M.: Nonpharmacologic treatment of cocaine abuse. Psychiatr Clin North Am 9:563–571, 1986.PubMedGoogle Scholar
  29. 151.
    Weiss R. D.: Relapse to cocaine abuse after initiating desipramine treatment. JAMA 260:2545–2546, 1988.PubMedCrossRefGoogle Scholar
  30. 152.
    Weiss R. D., Gawin F. H.: Protracted elimination of cocaine metabolites in long term high-dose cocaine abusers. Am J Med 85:879–880, 1988.PubMedCrossRefGoogle Scholar
  31. 153.
    Weiss R. D., Mirin S. M.: Cocaine. Washington, American Psychiatric Press, 1987.Google Scholar
  32. 154.
    Weiss R. D., Mirin S. M.: Subtypes of cocaine abusers. Psychiatr Clin North Am 9:491–501, 1986.PubMedGoogle Scholar
  33. 155.
    Weiss R. D., Mirin S. M., Griffin M. L., et al: Psychopathology in cocaine abusers: Changing trends. J Nerv Ment Dis 176:719–725, 1988.PubMedCrossRefGoogle Scholar
  34. 156.
    Weiss R. D., Mirin S. M., Michael J. L., et al: Psychopathology in chronic cocaine abusers. Am J Drug Alcohol Abuse 12:17–29, 1986.PubMedCrossRefGoogle Scholar
  35. 157.
    Woods, J. R., Plessinger M. A., Clark K. E.: Effect of cocaine on uterine blood flow and fetal oxygenation. JAMA 257:957–961, 1987.PubMedCrossRefGoogle Scholar


  1. 158.
    Abraham H. D.: Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 40:884–889, 1983.PubMedCrossRefGoogle Scholar
  2. 159.
    Blacker K. H., Reese T. J., Stone G. C., et al: Chronic users of LSD: The“acidheads.” Am J Psychiatry 125:341–351, 1968.Google Scholar
  3. 160.
    Bowers M. B., Jr.: Acute psychosis induced by psychotomimetic drug abuse. I. Clinical findings. Arch Gen Psychiatry 27:437–439, 1972.PubMedCrossRefGoogle Scholar
  4. 161.
    Bowers M. B., Jr.: Acute psychosis induced by psychotomimetic drug abuse. II. Neurochemical findings. Arch Gen Psychiatry 27:440–442, 1972.PubMedCrossRefGoogle Scholar
  5. 162.
    Bowers M. B., Jr., Chipman A., Schwartz A., et al: Dynamics of psychedelic drug abuse: A clinical study. Arch Gen Psychiatry 16:560–566, 1967.PubMedCrossRefGoogle Scholar
  6. 163.
    Brawley P., Duffield J. C.: The pharmacology of hallucinogens. Pharmacol Rev 24:31–66, 1972.PubMedGoogle Scholar
  7. 164.
    Cohen S.: Flashbacks. Drug Abuse Alcoholism Newslett 6:1–3, 1977.Google Scholar
  8. 165.
    Faillace L. A., Snyder S. H., Weingartner H.: 2,5-Dimethoxy-l-methylamphetamine: Clinical evaluation of a new hallucinogenic drug. J Nerv Ment Dis 150:119–126, 1970.PubMedCrossRefGoogle Scholar
  9. 166.
    Freedman D. X.: The use and abuse of LSD. Arch Gen Psychiatry 18:330–347, 1968.PubMedCrossRefGoogle Scholar
  10. 167.
    Gilmour D. G., Bloom A. D., Lele K. P., et al: Chromosomal aberrations in users of psychoactive drugs. Arch Gen Psychiatry 24:268–272, 1971.PubMedCrossRefGoogle Scholar
  11. 168.
    Glass G. S., Bowers M. B., Jr. : Chronic psychosis associated with long-term psychotomimetic drug abuse. Arch Gen Psychiatry 23:97–102, 1970.PubMedCrossRefGoogle Scholar
  12. 169.
    Grinspoon L., Bakalar J. B.: Psychedelic Drugs Reconsidered. New York, Basic Books, 1979.Google Scholar
  13. 170.
    Jacobson C. B., Berlin C. M.: Possible reproductive detriment in LSD users. JAMA 222:1367–1373, 1972.PubMedCrossRefGoogle Scholar
  14. 171.
    McGlothlin W. H., Arnold D. O.: LSD revisited. Arch Gen Psychiatry 24:35–49, 1971.PubMedCrossRefGoogle Scholar
  15. 172.
    McGlothlin W. H., Arnold D. O., Freedman D. X.: Organicity measures following repeated LSD ingestion. Arch Gen Psychiatry 21:704–709, 1969.PubMedCrossRefGoogle Scholar
  16. 173.
    Snyder S. H., Faillace L. A., Weingartner H.: DOM (STP), a new hallucinogenic drug, and DOET: Effects in normal subjects. Am J Psychiatry 125:113–120, 1968.PubMedGoogle Scholar
  17. 174.
    Snyder S. H., Weingartner H., Faillace L. A.: DOET (2,5-dimethoxy-4-ethylamphetamine), a new psychotropic drug: Effects of varying doses in man. Arch Gen Psychiatry 24:50–55, 1971.PubMedCrossRefGoogle Scholar
  18. 175.
    Tucker G. J., Quinlan D., Harrow M.: Chronic hallucinogenic drug use and thought disturbance. Arch Gen Psychiatry 27:443–447, 1972.PubMedCrossRefGoogle Scholar


  1. 176.
    Clouet D. H. (ed): Phencyclidine: An Update. Washington, National Institute on Drug Abuse, 1986.Google Scholar
  2. 177.
    Domino E. F.: Treatment of phencyclidine intoxication. Psychopharmacol Bull 16:83–85, 1980.PubMedGoogle Scholar
  3. 178.
    Fauman M. A., Fauman B. J.: The psychiatric aspects of chronic phencyclidine use: A study of chronic PCP users, in Peterson R. C., Stillman R. C. (eds): PCP: Phencyclidine Abuse: An Appraisal. Washington, National Institute on Drug Abuse, Research Monograph 21, DHEW Publ . No. 78–728, 1978, pp 183–200.Google Scholar
  4. 179.
    Gelenberg A. J.: Psychopharmacology update: Phencyclidine. McLean Hosp J 2:89–96, 1977.Google Scholar
  5. 180.
    Graeven D. B.: Patterns of phencyclidine use, in Peterson R. C., Stillman R. C. (eds): PCP: Phencyclidine Abuse: An Appraisal. Washington, National Institute on Drug Abuse, Research Monograph 21, DHEW Publ. No. 78–728, 1978, pp 176–182.Google Scholar
  6. 181.
    Luisada P. V.: The phencyclidine psychosis: Phenomenology and treatment, in Peterson R. C., Stillman R. C. (eds): PCP: Phencyclidine Abuse: An Appraisal. Washington, National Institute on Drug Abuse, Research Monograph 21, DHEW Publ. No. 78–728, 1978, pp 241–253.Google Scholar
  7. 182.
    Peterson R. C., Stillman R. C.: Phencyclidine: An overview, in Peterson R. C., Stillman R. C. (eds): PCP: Phencyclidine Abuse: An Appraisal. Washington, National Institute on Drug Abuse, Research Monograph 21, DHEW Publ. No. 78–728, 1978, pp 1–17.Google Scholar
  8. 183.
    Smith D. R., Wesson D. R., Buxton M. E., et al: The diagnosis and treatment of the PCP abuse syndrome, in Peterson R. C., Stillman R. C. (eds): PCP: Phencyclidine Abuse: An Appraisal. Washington, National Institute on Drug Abuse, Research Monograph 21, DHEW Publ. No. 78–728, 1978, pp 229–240.Google Scholar


  1. 184.
    Cohen S.: Inhalants, in DuPont R. L., Goldstein A., O’Donnell J. (eds): Handbook on Drug Abuse, Washington, National Institute on Drug Abuse, 1979, pp 213–220.Google Scholar
  2. 185.
    Glaser F. B.: Inhalation psychosis and related states, in Browne P. G. (ed): A Treatment Manual for Acute Drug Abuse Emergencies. Washington, National Institute on Drug Abuse, 1975, pp 95–104.Google Scholar
  3. 186.
    Lewis J. D., Moritz D., Mellis L. P.: Long-term toluene abuse. Am J Psychiatry 138:368–370, 1981.PubMedGoogle Scholar
  4. 187.
    Westermeyer J.: The psychiatrist and solvent–inhalant abuse: Recognition, assessment, and treatment. Am J Psychiatry 144:903–907, 1987.PubMedGoogle Scholar


  1. 188.
    Benedikt R. A., Cristofaro P., Mendelson J. H., et al: Effects of acute marijuana smoking in postmenopausal women. Psychopharmacology 90:14–17, 1986.PubMedCrossRefGoogle Scholar
  2. 189.
    Bernstein J. G.: Marijuana—new potential, new problems. Drug Ther10:38–48, 1980.Google Scholar
  3. 190.
    Chopra G. S., Smith J. W.: Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 30:24–27, 1974.PubMedCrossRefGoogle Scholar
  4. 191.
    Cohen S.: Cannabis: Impact on motivation. Part I. Drug Abuse Alcoholism Newslett 9:1–3, 1980.Google Scholar
  5. 192.
    Cohen S.: Cannabis: Impact on motivation. Part II. Drug Abuse Alcoholism Newslett 10:1–3, 1981.Google Scholar
  6. 193.
    Harding T., Knight F.: Marijuana-modified mania. Arch Gen Psychiatry 29:635–637, 1973.CrossRefGoogle Scholar
  7. 194.
    Jones R. T.: Marijuana-induced“high“: Influence of expectation, setting and previous drug experience. Pharmacol Rev 23:359–369, 1971.PubMedGoogle Scholar
  8. 195.
    Kupfer D. J., Detre T., Koral J., et al: A comment on the“amotivational syndrome“ in marijuana smokers. Am J Psychiatry 130:1319–1322, 1973.PubMedGoogle Scholar
  9. 196.
    Melges F. T., Tinklenberg J. R., Hollister L. E., et al: Temporal disintegration and depersonalization during marijuana intoxication. Arch Gen Psychiatry 23:204–210, 1970.PubMedCrossRefGoogle Scholar
  10. 197.
    Mendelson J. H.: Marijuana, in Meltzer H. Y. (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 1565–1571.Google Scholar
  11. 198.
    Mendelson J. H., Ellingboe J., Kuehnle J. C., et al: Effects of chronic marijuana use on integrated plasma testosterone and luteinizing hormone levels. J Pharmacol Exp Ther 207:611–617, 1978.PubMedGoogle Scholar
  12. 199.
    Mendelson J. H., Mello N. K., Ellingboe J., et al: Marijuana smoking suppresses luteinizing hormone in women. J Pharmacol Exp Ther 237:862–886, 1986.PubMedGoogle Scholar
  13. 200.
    Mendelson J. H., Rossi A. M., Meyer R. E. (eds): The Use of Marijuana: A Psychological and Physiological Inquiry. New York, Plenum Press, 1974.Google Scholar
  14. 201.
    Meyer R. E.: Psychiatric consequences of marijuana use: The state of the evidence, in Tinklenberg J. R. (ed): Marijuana and Health Hazards. Methodological Issues in Current Research. New York, Academic Press, 1975, pp 133–152.Google Scholar
  15. 202.
    Millman R. B., Sbriglio R.: Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North Am 9:533–545, 1986.PubMedGoogle Scholar
  16. 203.
    Mirin S. M., Shapiro L. M., Meyer R. E., et al: Casual versus heavy use of marijuana: A redefinition of the marijuana problem. Am J Psychiatry 127:54–60, 1971.Google Scholar
  17. 204.
    Peterson R. C. (ed): Marijuana Research Findings: 1980. Washington, National Institute on Drug Abuse, Research Monograph 31, 1980.Google Scholar
  18. 205.
    Schnoll S. H., Daghestani A. N.: Treatment of marijuana abuse. Psychiatr Ann 16:249–257, 1986.Google Scholar
  19. 206.
    Tashkin D. P., Shapiro B. J., Lee Y. E.: Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. N Engl J Med 294:125–129, 1976.PubMedCrossRefGoogle Scholar
  20. 207.
    Tennant F. S.: The clinical syndrome of marijuana dependence. Psychiatr Ann 16:225–234, 1986.Google Scholar
  21. 208.
    Tennant F. S., Jr., Groesbeck C. J.: Psychiatric effects of hashish. Arch Gen Psychiatry 27:133–136, 1972.PubMedCrossRefGoogle Scholar
  22. 209.
    Thacore V. R., Shukla S. R. P.: Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 33:383–386, 1976.PubMedCrossRefGoogle Scholar
  23. 210.
    Treffert D. A.: Marijuana use in schizophrenia: A clear hazard. AmJ Psychiatry 135:1213–1220, 1978.Google Scholar
  24. 211.
    Weil A. T.: Adverse reactions to marijuana: Classification and suggested treatment. N Engl J Med 282:997–1000, 1970.PubMedCrossRefGoogle Scholar
  25. 212.
    Wu T., Tashkin D. P., Djahed B., et al: Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 318:347–351, 1988.PubMedCrossRefGoogle Scholar
  26. 213.
    Zuckerman B., Frank D. A., Hingson R., et al: Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320:762–768, 1989.PubMedCrossRefGoogle Scholar

“Designer“ Drugs: MDMA and MDEA

  1. 214.
    Dowing G. P., McDonough E. T., Bost R. O.: ‘Eve’ and ‘ecstasy’: A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615–1617, 1987.CrossRefGoogle Scholar
  2. 215.
    Greer G., Strassman R. J.: Information on“ecstasy.“ Am J Psychiatry 142:1391, 1985.PubMedGoogle Scholar
  3. 216.
    Newmeyer J. A.: Some considerations on the prevalence of MDMA use. J Psychoactive Drugs 18:361–362, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Steven M. Mirin
    • 1
    • 2
  • Roger D. Weiss
    • 3
    • 2
  • Shelly F. Greenfield
    • 1
    • 2
  1. 1.McLean HospitalBelmontUSA
  2. 2.Department of PsychiatryHarvard Medical SchoolBostonUSA
  3. 3.Alcohol and Drug Abuse ProgramMcLean HospitalBelmontUSA

Personalised recommendations